Skip to main content

Table 1 Demographic and clinical data at baseline

From: Alzheimer’s Disease Assessment Scale–Cognitive subscale variants in mild cognitive impairment and mild Alzheimer’s disease: change over time and the effect of enrichment strategies

 

MCI

MCI+

MCI−

Mild AD

Mild AD+

Number of subjects (100 %)

382

206

176

97

90

Female (%)

43 %

42 %

45 %

45 %

48 %

Caucasian, n (%)

94 %

97 %

90 %

96 %

96 %

Age, yr

71.97 ± 7.39

72.97 ± 7.10

70.80 ± 7.56

75.17 ± 7.70

74.85 ± 7.66

Education, yr

16.28 ± 2.59

16.31 ± 2.62

16.25 ± 2.55

15.52 ± 2.60

15.51 ± 2.58

ApoE4 at risk,a n (%)

177 (46 %)

142 (69 %)

35 (20 %)

67 (69 %)

65 (72 %)

MMSE

27.85 ± 1.75

27.41 ± 1.82

28.37 ± 1.52

23.19 ± 1.99

23.14 ± 1.99

CDR global

0.50 ± 0.00

0.50 ± 0.00

0.50 ± 0.00

0.77 ± 0.28

0.77 ± 0.28

CDR-SB

1.40 ± 0.84

1.56 ± 0.92

1.21 ± 0.70

4.40 ± 1.71

4.41 ± 1.65

ADAS-Cog 11

9.50 ± 4.29

10.83 ± 4.46

7.94 ± 3.50

19.66 ± 6.30

20.14 ± 6.26

ADAS-Cog 3

8.23 ± 3.76

9.43 ± 3.92

6.82 ± 3.02

15.95 ± 4.15

16.28 ± 4.12

ADAS-Cog 5

13.96 ± 6.17

16.12 ± 6.28

11.43 ± 4.99

26.20 ± 5.31

26.62 ± 5.23

ADAS-Cog 13

15.23 ± 6.68

17.52 ± 6.81

12.55 ± 5.43

29.91 ± 7.44

30.52 ± 7.35

  1. amyloid-β, AD Alzheimer’s disease, ADAS-Cog Alzheimer’s Disease Assessment Scale–Cognitive subscale, ApoE4, apolipoprotein E ε4, CDR Clinical Dementia Rating, MCI mild cognitive impairment, MMSE Mini Mental State Examination, SB Sum of Boxes
  2. Populations enriched based on t- Tau/Aβ ratio are labelled as MCI+ and AD+. Data are presented as mean ± standard deviation unless indicated otherwise
  3. aApoE4 status is not available for one subject in the MCI group